Humana Inc. (NYSE:HUM) Shares Acquired by Keybank National Association OH

Posted by Defense World Staff on Aug 20th, 2023

Keybank National Association OH grew its stake in shares of Humana Inc. (NYSE:HUM – Free Report) by 21.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,922 shares of the insurance provider’s stock after buying an additional 335 shares during the quarter. Keybank National Association OH’s holdings in Humana were worth $933,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in HUM. U.S. Capital Wealth Advisors LLC bought a new stake in Humana during the fourth quarter worth approximately $35,000. MV Capital Management Inc. lifted its holdings in shares of Humana by 40.8% in the first quarter. MV Capital Management Inc. now owns 69 shares of the insurance provider’s stock valued at $33,000 after buying an additional 20 shares during the period. Householder Group Estate & Retirement Specialist LLC acquired a new position in Humana during the first quarter worth about $39,000. Delta Asset Management LLC TN bought a new stake in Humana in the fourth quarter worth about $46,000. Finally, Edge Capital Group LLC lifted its holdings in Humana by 1,940.0% in the 4th quarter. Edge Capital Group LLC now owns 102 shares of the insurance provider’s stock valued at $52,000 after acquiring an additional 97 shares during the last quarter. 93.21% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

Shares of NYSE HUM opened at $490.39 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.37 and a quick ratio of 1.37. Humana Inc. has a one year low of $423.29 and a one year high of $571.30. The business’s 50-day moving average price is $460.45 and its two-hundred day moving average price is $490.46. The company has a market capitalization of $60.76 billion, a P/E ratio of 18.30, a price-to-earnings-growth ratio of 1.26 and a beta of 0.67.

Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $8.94 EPS for the quarter, beating the consensus estimate of $8.88 by $0.06. The business had revenue of $26.75 billion during the quarter, compared to analysts’ expectations of $25.83 billion. Humana had a return on equity of 20.70% and a net margin of 3.42%. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $8.67 EPS. Analysts anticipate that Humana Inc. will post 28.26 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 29th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 0.72%. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s dividend payout ratio is presently 13.21%.

Analysts Set New Price Targets

HUM has been the topic of a number of research reports. Sanford C. Bernstein boosted their target price on shares of Humana from $568.00 to $599.00 and gave the stock a “market perform” rating in a report on Tuesday, August 8th. JPMorgan Chase & Co. downgraded Humana from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $576.00 to $540.00 in a research report on Friday, July 7th. Mizuho decreased their target price on Humana from $615.00 to $550.00 in a report on Tuesday, July 11th. SVB Securities reduced their target price on Humana from $640.00 to $600.00 in a report on Thursday, April 27th. Finally, Argus cut Humana from a “buy” rating to a “hold” rating in a research note on Friday, June 23rd. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $592.95.

Get Our Latest Report on Humana

Humana Company Profile

(Free Report)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.